Viral protein-Human antibody complex

Macromolecule
Gene
Interacting molecule/ protein
Interacting gene
PDB ID
Title
Structure Title
Experimental Method
Resolution (Å)
PubMed ID
Structure
Spike glycoprotein
S, 2
CR3022 Fab Heavy Chain CR3022 Fab Light Chain
~
7A5S
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement)
Electron Microscopy
3.9
33087721
3D view
Spike glycoprotein
S, 2
CR3022 Fab Heavy Chain CR3022 Fab Light Chain
~
7A5R
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement)
Electron Microscopy
3.7
33087721
3D view
Spike glycoprotein
S, 2
Antibody Cr3022, Antibody light chain, Nanobody
~
6YZ7
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex
X-ray diffraction
3.3
To be published
3D view
Spike glycoprotein
S, 2
Nanobody, EY6A heavy chain, EY6A light chain
~
6ZCZ
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.
X-ray diffraction
2.65
32737466
3D view
Spike glycoprotein
S, 2
EY6A heavy chain, EY6A light chain
~
6ZDH
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab
Electron Microscopy
3.7
32737466
3D view
Spike glycoprotein
S, 2
EY6A heavy chain, EY6A light chain
~
6ZDG
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab
Electron Microscopy
4.7
32737466
3D view
RBD
S, 2
EY6A Fab
~
6ZER
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab
X-ray diffraction
3.8
32737466
3D view
Spike glycoprotein
S, 2
EY6A heavy chain, EY6A light chain
~
6ZFO
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab
Electron Microscopy
4.4
32737466
3D view
Surface glycoprotein
S
STE90-C11 Fab
~
7B3O
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations
Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab
X-ray diffraction
2
3D view
Spike glycoprotein
S,2
CR3022 heavy chain, CR3022 Light chain, Nanobody H11-H4
~
6ZH9
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2)
X-ray diffraction
3.31
32661423
3D view
Spike glycoprotein (A,E chains)
S,2
CR3022 Fab
~
6YLA
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab
X-ray diffraction
2.42
32585135
3D view
Spike glycoprotein
S,2
CR3022 Fab
~
6YM0
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1)
X-ray diffraction
4.36
32585135
3D view
Spike glycoprotein
S,2
IgG H chain, IgG L chain
~
6YOR
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab
Electron Microscopy
3.3, 3.9
32585135
3D view
Spike glycoprotein
S,2
CR3022 antibody, H11-D4
~
6Z2M
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex
X-ray diffraction
2.71
To be published
3D view
Spike glycoprotein - S1
S,2
CV07-250 ( heavy and light chain)
~
6XKQ
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250
X-ray diffraction
2.55
33058755
3D view
Spike protein S1
S,2
CV07-270 (heavy and light chain)
~
6XKP
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270
X-ray diffraction
2.72
33058755
3D view
Spike protein
S,2
3C1 mAb ( heavy chain and light chain)
~
7DD2
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.
Electron Microscopy
5.6
Nature Communications volume 12, Article number: 264 (2021)
3D view
SARC-CoV2 S protein
S,2
Heavy and light chain of 3C1 fab
~
7DCC
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab
Electron Microscopy
4.3
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
The heavy and light chain of 3C1 fab that binds with the up RBD
~
7DCX
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.
Electron Microscopy
5.9
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
The heavy and light chain of 3C1 fab
~
7DD8
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab
Electron Microscopy
7.5
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
S2M11 Fab fragment (heavy and light chain)
~
7K43
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment
Electron Microscopy
2.6
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
S2E12 neutralizing antibody Fab fragment (heavy and light chain)
7K45
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains)
Electron Microscopy
3.7
32972994
3D view
Spike glycoprotein
S,2
Heavy and light chain of 2H2 Fab
~
7DK6
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.
Electron Microscopy
4.3
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
Heavy and light chain of 2H2 Fab
~
7DK7
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.
Electron Microscopy
9.7
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
Heavy and light chain of 2H2 Fab
~
7DK4
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.
Electron Microscopy
3.8
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
Heavy and light chain of 2H2 Fab
~
7DK5
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab
Electron Microscopy
13.5
Nature Communications volume 12, Article number: 264 (2021)
3D view
Spike glycoprotein
S,2
CB6 heavy and light chain
~
7C01
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD
X-ray diffraction
2.88
32454512
3D view
Spike glycoprotein
S,2
4A8 ( heavy and light chain )
~
7C2L
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
S protein of SARS-CoV-2 in complex bound with 4A8
Electron Microscopy
3.1
32571838
3D view
SARS-CoV-2 receptor binding domain
S,2
P2B-2F6 ( heavy and light chain )
~
7BWJ
Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Crystal structure of SARS-CoV-2 antibody with RBD
X-ray diffraction
2.85
32454513
3D view
Spike glycoprotein
S,2
B38 antibody (heavy and light chain)
~
7BZ5
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.
Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody
X-ray diffraction
1.84
32404477
3D view
SARS-CoV-2 Spike glycoprotein
S,2
Ab23-Fab(Heavy and light chain)
~
7BYR
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
BD23-Fab in complex with the S ectodomain trimer
Electron Microscopy
3.84
32425270
3D view
Spike glycoprotein
S,2
H014 (heavy and light chain)
~
7CAH
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.
The interface of H014 Fab binds to SARS-CoV-2 S
Electron Microscopy
3.9
32703908
3D view
Spike glycoprotein
S,2
H014 (heavy and light chain)
~
7CAK
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.
SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab
Electron Microscopy
3.58
32703908
3D view
Spike glycoprotein
S,2
H014 (heavy and light chain)
~
7CAI
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.
SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab
Electron Microscopy
3.49
32703908
3D view
Spike protein S1
S,2
P2C-1A3 ( heavy and light chain )
~
7CDJ
Crystal structure of SARS-CoV-2 antibody P2C-1A3 and RBD
Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD
X-ray diffraction
3.396
To be published
3D view
Spike protein S1
S,2
Antibody P2C-1F11 heavy and light chain
~
7CDI
Crystal structure of SARS-CoV-2 antibody P2C-1F11 and RBD
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD
X-ray diffraction
2.96
To be published
3D view
Spike glycoprotein
S,2
BD-604 Fab ( Heavy and light chain)
~
7CH4
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab
X-ray diffraction
3.15
32970990
3D view
Spike glycoprotein
S,2
BD-629 Fab ( Heavy and light chain)
~
7CH5
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab
X-ray diffraction
2.7
32970990
3D view
SARS-CoV-2 Receptor Binding Domain
S,2
BD-604 Fab ( Heavy and light chain) BD-368-2 Fab (heavy and light chain)
~
7CHF
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab
X-ray diffraction
2.674
32970990
3D view
SARS-coV-2 Receptor Binding Domain
BD-236 Fab (heavy and light chain) BD-368-2 Fab ( heavy and light chain)
~
7CHE
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab
X-ray diffraction
3.416
32970990
3D view
Spike glycoprotein
S,2
BD-368-2 Fab (heavy and light chain )
~
7CHH
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs
Electron Microscopy
3.49
32970990
3D view
SARS-coV-2 Receptor Binding Domain
S,2
BD-236 Fab ( heavy and light chain )
~
7CHB
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab
X-ray diffraction
2.4
32970990
3D view
BD-629 Fab H
S,2
BD-629 Fab Heavy chain IGK@ protein BD-368-2 Fab ( Heavy and light chain )
IGK@
7CHC
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab
X-ray diffraction
2.71
32970990
3D view
Spike glycoprotein
S,2
Antibody heavy and light chain
~
7CJF
Crystal structure of SARS-CoV-2 RBD in complex with an antibody Fab
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab
X-ray diffraction
2.108
To be published
3D view
Spike glycoprotein
S,2
P17 and FC05 Fabs (heavy and light chains)
~
7CWU
Structure-based development of human antibody cocktails against SARS-CoV-2.
SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail
Electron Microscopy
3.5
33262454
3D view
Spike glycoprotein
S,2
FC05 and H014 Fabs ( heavy and light chains )
~
7CWS
Structure-based development of human antibody cocktails against SARS-CoV-2.
SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail
Electron Microscopy
3.4
33262454
3D view
Spike glycoprotein
S,2
P17 heavy and light chain
~
7CWM
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.
Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state
Electron Microscopy
3.6
33262452
3D view
Spike glycoprotein
S,2
P17-H014 Fab ( heavy and light chain )
~
7CWN
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.
P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein
Electron Microscopy
3.2
33262452
3D view
Spike glycoprotein
S,2
P17 ( heavy and light chain )
~
7CWO
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection.
SARS-CoV-2 spike protein RBD and P17 fab complex
Electron Microscopy
3.9
33262452
3D view
Spike protein S1
S,2
COVA1-16 (heavy and light chain)
~
7JMW
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab
X-ray diffraction
2.89
33242394
3D view
Spike protein S1
S,2
COVA2-39 (heavy and light chain)
~
7JMP
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39
X-ray diffraction
1.712
32743580
3D view
Spike protein S1
S,2
COVA2-04 (heavy and light chain)
~
7JMO
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain.
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04
X-ray diffraction
2.359
32743580
3D view
Spike glycoprotein
S,2
S2E12 neutralizing antibody Fab fragment (heavy and light chain)
~
7K4N
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment
Electron Microscopy
3.3
32972994
3D view
Spike glycoprotein
S,2
S2A4 Fab( heavy and light chain)
~
7JVA
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains)
Electron Microscopy
3.6
32991844
3D view
Spike glycoprotein
S,2
S2H13 Fab (heavy and light chain)
~
7JV6
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation)
Electron Microscopy
3
32991844
3D view
Spike glycoprotein
S,2
S2H13 Fab (heavy and light chain)
~
7JV4
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open)
Electron Microscopy
3.4
32991844
3D view
Spike glycoprotein
S,2
S2H13 Fab (heavy and light chain)
~
7JV2
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains)
Electron Microscopy
3.5
32991844
3D view
Spike glycoprotein
S,2
autonomous human heavy chain variable domain
~
7JWB
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
SARS CoV2 Spike ectodomain with engineered trimerized VH binder
Electron Microscopy
6, 3.2
33082574
3D view
Spike glycoprotein
S,2
S304 Fab (light and heavy chain)
~
7JW0
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment
Electron Microscopy
4.3
32991844
3D view
Spike glycoprotein
S,2
S2A4 Fab (heavy and light chain)
~
7JVC
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment
Electron Microscopy
3.3
32991844
3D view
Spike glycoprotein
S,2
C110 Fab (Heavy and light chain)
~
7K8V
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110
Electron Microscopy
3.8
33045718
3D view
Spike glycoprotein
S,2
C119 Fab (Heavy and light chain)
~
7K8W
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119
Electron Microscopy
3.6
33045718
3D view
Spike glycoprotein
S,2
C002 Fab (Heavy and light chain)
~
7K8T
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)
Electron Microscopy
3.4
33045718
3D view
Spike glycoprotein
S,2
C104 Fab (Heavy and light chain)
~
7K8U
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104
Electron Microscopy
3.8
33045718
3D view
Spike glycoprotein
S,2
C135 Fab (Heavy and light chain)
~
7K8Z
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135
Electron Microscopy
3.5
33045718
3D view
Spike glycoprotein
S,2
C121 Fab (Heavy and light chain)
~
7K8X
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)
Electron Microscopy
3.9, 3.9
33045718
3D view
Spike glycoprotein
S,2
C121 Fab (Heavy and light chain)
~
7K8Y
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)
Electron Microscopy
4.4, 4.4
33045718
3D view
Spike glycoprotein
S,2
C144 Fab (Heavy and light chain)
~
7K90
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144
Electron Microscopy
3.24
33045718
3D view
Spike glycoprotein
S,2
C102 Fab (Heavy and light chain)
~
7K8M
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102
X-ray diffraction
3.2
33045718
3D view
Spike glycoprotein
S,2
Light and heavy chain of Fab domain of monoclonal antibodies S309, S2H14, S304
~
7JX3
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology
X-ray diffraction
2.65
32991844
3D view
Spike glycoprotein
S,2
C002 Fab (Heavy and light chain)
~
7K8S
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)
Electron Microscopy
3.4
33045718
3D view
Spike glycoprotein
S,2
Antibodies 52, 298 Fab (light and heavy chains)
~
7K9Z
Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers
Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52
X-ray diffraction
2.95
To be published
3D view
Surface glycoprotein
S,2
human antibody C1A-C2 Fab (heavy and light chain)
~
7KFX
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab)
X-ray diffraction
2.226
33200128
3D view
Surface glycoprotein
S,2
Human antibody C1A-F10 Fab (heavy and light chain)
~
7KFY
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab)
X-ray diffraction
2.157
33200128
3D view
Surface glycoprotein
S,2
Human antibody C1A-B12 Fab (heavy and light chain)
~
7KFV
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab)
X-ray diffraction
2.102
33200128
3D view
Surface glycoprotein
S,2
Human antibody C1A-B3Fab (heavy and light chain)
~
7KFW
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab)
X-ray diffraction
2.792
33200128
3D view
Spike glycoprotein S1
S,2
CR3022 Fab ( heavy and light chain)
~
6W41
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV.
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022
X-ray diffraction
3.084
32245784
3D view
Spike glycoprotein
S,2
Antibody S309 ( heavy and light chain)
~
6WPT
Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state)
Electron Microscopy
3.7, 3.7
32511354
3D view
Spike glycoprotein
S,2
Antibody S309 ( heavy and light chain)
~
6WPS
Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment
Electron Microscopy
3.1, 3.1
32511354
3D view